Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke

The Lancet

Volumn 342, Issue 8882, 1993, Pages 1255-1262

 

^a European Atrial Fibrillation Trial) Study Group

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMAN; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; RECURRENCE; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 0027505093     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(93)92358-Z     Document Type: Article

References (31)

1. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study
2. The secondary prevention of stroke in patients with atrial fibrillation
3. Cardiogenic brain embolism second report
4. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study
5. Letter to the editor
6. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation study
7. Stroke Prevention in Atrial Fibrillation. Final results
8. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
9. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
10. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
11. Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
12. Non-rheumatic atrial fibrillation: warfarin or aspirin for all? Neurological comment
13. Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillations
14. Cause of cerebral infarction in the carotid territory. Its relation to the size and the location of the infarct and to the underlying vascular lesion
15. Hemorrhagic complications of long-term anticoagulant therapy for ischemic cerebral vascular disease
16. Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulation prophylaxis
17. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report
18. Cardiac sources of embolism and cerebral infarction-clinical consequences and vascular concomitants: The Lausanne Stroke Registry
19. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism
20. Secondary prevention of vascular disease by prolonged antiplatelet treatment
21. Interobserver agreement for the assessment of handicap in stroke patients
22. Interobserver agreement for the assessment of handicap in stroke patients (letter to editor)
23. Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation
24. Antithrombotic therapy in atrial fibrillation
25. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options
26. Cardioembolic stroke early anticoagulation and brain hemorrhage
27. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy
28. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials
29. Atrial fibrillation and anticoagulation: from randomised trials to practice